Pharmos to Present at the BIO 2005 Business Forum

Pharmos to Present at the BIO 2005 Business Forum 


ISELIN, N.J., June 16  /PRNewswire-FirstCall/ -- Pharmos Corporation
(NASDAQ:PARSD) today announced that it will present at the BIO 2005 Business
Forum on Wednesday, June 22, 2004 at 11:30 am Eastern Time at the Pennsylvania
Convention Center in Philadelphia, Pennsylvania. Gad Riesenfeld, Ph.D.,
President and Chief Operating Officer, will provide an update on the Company's
business and product pipeline.

According to the Biotechnology Industry Organization (BIO), this year's Annual
International Convention will be the world's largest biotechnology gathering,
with an anticipated 18,000 attendees and over 1,500 exhibiting companies and
organizations. Each year the BIO Business Forum provides an arena for
pharmaceutical companies, biotechnology companies, academic research institutes
and investors to meet and explore mutually beneficial opportunities.

Pharmos discovers and develops novel therapeutics to treat a range of
indications, in particular neurological and inflammatory disorders. The
Company's core proprietary technology platform focuses on discovery and
development of synthetic cannabinoid compounds. Cannabinor, the lead
CB2-selective receptor agonist candidate, is scheduled to begin Phase I safety
studies in the second half of 2005 and, if successful, enter Phase II testing
in pain indications around yearend or early 2006. From the dextrocannabinoid
family, the neuroprotective drug candidate dexanabinol recently completed a
Phase IIa trial as a preventive agent against post-surgical cognitive
impairment. Other compounds from Pharmos' proprietary synthetic cannabinoid
library are in pre-clinical studies targeting pain, multiple sclerosis,
rheumatoid arthritis and other disorders.

Statements made in this press release related to the business outlook and
future financial performance of the Company, to the prospective market
penetration of its drug products, to the development and commercialization of
the Company's pipeline products and to the Company's expectations in connection
with any future event, condition, performance or other matter, are
forward-looking and are made pursuant to the safe harbor provisions of the
Securities Litigation Reform Act of 1995. Such statements involve risks and
uncertainties which may cause results to differ materially from those set forth
in these statements. Additional economic, competitive, governmental,
technological, marketing and other factors identified in Pharmos' filings with
the Securities and Exchange Commission could affect such results. 

DATASOURCE: Pharmos Corporation



CONTACT:  Pharmos U.S. - Gale Smith, [phone], or Pharmos Israel -

Irit Kopelov, [phone]; or Investors - John Quirk, [phone], or

Media - Janine McCargo, [phone], both of The Ruth Group, Inc., for

Pharmos Corporation



Web site:  http://www.pharmoscorp.com/ 

Copyright